COYA (Coya Therapeutics) תחזית צמיחת רווחים לשנה הבאה

Coya Therapeutics, Inc. (COYA) focuses on neuroimmunology, attracting experts through innovative Treg therapy and the fight against Parkinson's disease. Analyst valuations based on n+1 net profit dynamics demonstrate market expectations, where -2.50 is recorded as the baseline value. Coya Therapeutics, Inc. (COYA) retains rare specialists through R&D programs and RSUs. Positive tests against ALS are creating momentum, although Phase II catalysts are still forming.
פילוחים אנליטיים ודוחות נתונים של חברת Coya (COYA)

This indicator aggregates analyst consensus forecasts for changes in earnings per share, reflecting the expected business efficiency over the short term. For Coya Therapeutics, Inc. (COYA), which is burning capital on T-cell clinical trials, the outlook for EPS changes next year serves as a speculative indicator of market confidence in the success of its developments. The high volatility of this metric underscores the lack of stable cash flow and the elevated investment risk.